^
Association details:
| Biomarker: | IDH2 R140Q |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | Idhifa (enasidenib) (IDH2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations
Excerpt:
AG-221 also provided a statistically significant survival benefit in an aggressive IDH2R140Q-mutant AML xenograft mouse model.
DOI:
10.1158/2159-8290.CD-16-1034
